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persons, and C,—with surgery to cure the disease itself or its
complications, 18 persons. The average costs were 1060€ per
person and year. The average of yearly costs per person in the
subgroup A were 485€; in the subgroup B it was 1500€, and in
the subgroup C, it was 1,530€. The highest costs per one patient
in the subgroup B were 4265€ and in subgroup C it was 6255€.
The ratio of own patients to all costs was 17.5%, to health care
costs 72.1%, and to social costs 10.4%. Pharmacotherapy
reached 49.7% of the total costs, diagnostic procedures 0.9%,
ambulatory care 19.0%, hospital care 26%, spa care and travel
costs 4.4%. CONCLUSIONS: Crohnxs disease belongs to the
more expensive diseases in the Slovak Republic. There is a sig-
niﬁcant difference in the ratio-structure of costs in comparison
with western countries and the USA. Next pharmacoeconomic
studies in the Slovak Republic should be designed as prospec-
tive, cost of utility studies.
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OBJECTIVES: Overlap of gastro-oesophageal reﬂux disease
(GERD) and peptic ulcer disease (PUD) in a population with high
prevalence of Helicobacter pylori infections creates clinical
dilemmas in Hong Kong. Testing and eradication of H. pylori
may be a cost-effective alternative for empirical proton-pump
inhibitor (PPI) therapy. To examine the potential clinical and eco-
nomic impact of H. pylori “test and treat” and empirical PPI
therapy for GERD patients with typical reﬂux and high preva-
lence of H. pylori infection. METHODS: A Markov model was
designed to simulate the outcomes of the two treatment strate-
gies over 12 months. The transition probabilities and resource
utilization were derived from literature. Percentage of patients
with PUD treated, total number of quality-adjusted life-years
(QALY’s) gained and total direct medical cost were estimated.
RESULTS: H. pylori “test & treat” was more effective (92.6%
ulcer treated and 0.919 QALYs gained) than empirical PPI
(72.6% ulcer treated and 0.909 QALYs gained). The direct
medical cost per patient in the H. pylori “test and treat” and
empirical PPI arms were USD1901 and USD1770, respectively.
The direct medical cost per patient was sensitive to the variation
of the prevalence of PUD in H. pylori-infected GERD patients.
CONCLUSIONS: H. pylori “test & treat” appeared to be more
effective than empirical PPI therapy, with an incremental cost,
for GERD patients with typical reﬂux in Hong Kong.
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OBJECTIVES: To assess health related quality of life (QOL) and
its predictors among Polish patients with gastroesophageal reﬂux
disease (GERD). METHODS: National survey study was carried
out among 192 Polish general practitioners on out-patients pre-
senting with GERD symptoms. Data on patients’ clinical char-
acteristics, symptoms, treatment and QOL were collected. The
Carlsson’s diagnostic test was used to assess symptoms. A cut-
off score of four or higher was considered positive for GERD.
QOL was measured with SF-36. For the statistical hypothesis
testing the signiﬁcance threshold was set to 0.01. RESULTS:
Data on QOL was collected for 3290 patients, mean age: 
48.9 years (95%CI: 48.4–49.4; males: 47.8% (95%CI:
46.1%–49.5%). Mean health related QOL score was 58.5
(95%CI: 57.9–59.2). Patients with longer history of GERD-asso-
ciated symptoms reported statistically signiﬁcantly lower QOL
(19.1% decrease in QOL for patients with gastroesophageal
reﬂux disease history lasting for ﬁve to 10 years compared to
patients reporting it for less than three months). Adjusting for
case-mix the following symptoms were associated with statisti-
cally signiﬁcantly lower QOL: dysphagia, odynophagia, weight
loss, anaemia, age over 65, hoarseness, rhonchus, fullness, vom-
iting, while heartburn and chest pain or burning sensation and
chronic cough were not. CONCLUSIONS: GERD is associated
with poor QOL, especially for chronic patients. Some symptoms
represent good predicting value for QOL deterioration.
PGI11
PSYCHOMETRIC VALIDATION OF TWO GASTROINTESTINAL
(GI)-SPECIFIC PATIENT-REPORTED OUTCOME (PRO)
INSTRUMENTS IN RENAL TRANSPLANT PATIENTS WITH
AND WITHOUT GI COMPLICATIONS
Kleinman L1, Bahner U2, Faull R3,Walker R4, Prasad R5,Ambuehl P6,
Machnicki G7, Margolis MK1
1Medtap International, Seattle, WA, USA; 2KfH Kuratorium fur Dialyse
un Nierentrasnplantation, Wurzburg, Germany; 3Royal Adelaide
Hospital, Adelaide, Australia; 4The Royal Melbourne Hospital, Parkville,
Australia; 5St. Michael’s Hospital,Toronto, Ontario, Canada; 6University
Hospital Zurich, Zurich, Switzerland; 7Novartis Pharma AG, Basel,
Switzerland
OBJECTIVES: Gastrointestinal (GI) complications associated
with immunosuppressants are frequently reported by renal trans-
plant recipients. Mycophenolic acid has been associated with an
increased incidence of GI complaints. GI complications may
affect patient Quality of Life (QoL). The purpose of this study
was to psychometrically validate two GI-speciﬁc patient-
reported outcome (PRO) instruments in the renal transplant pop-
ulation. METHODS: The Gastrointestinal Symptom Rating
Scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI)
were selected for validation. Renal transplant recipients receiv-
ing a calcineurin inhibitor and mycophenolate mofetil were
recruited in a cross-sectional study from 5 clinical centers across
4 countries. Patients completed the GSRS, GIQLI, Psychological
General Well-Being Index (PGWB) and EQ-5D. Statistical analy-
ses employed Cronbach’s alpha, correlations, t-tests and
ANOVA. RESULTS: Of 96 patients recruited (mean age: 47.4 +
12.3 years; male: 56%), 41 (43%) suffered from no, 37 (39%)
mild, 12 (13%) moderate, and 6 (6%) severe GI symptoms.
Internal consistency reliability (Cronbach’s alpha) was >0.7 for
all GIQLI and all but 1 of the GSRS dimensions (abdominal
pain). Correlations between GIQLI and PGWB and EQ-5D were
higher (range: 0.24–0.76) than correlations between GSRS and
PGWB and EQ-5D (range: 0.05–0.54). All GSRS subscales and
the GIQLI total score and 4 subscales signiﬁcantly differentiated
between patients with and without GI complications (p < 0.05),
as did the PGWB total score and EQ-5D. The generic instru-
ments were unable to discriminate between GI severity levels;
conversely, the disease-speciﬁc instruments discriminated to
some extent between GI severity levels. GSRS abdominal pain
subscale discriminated between patients at all levels of severity
